Edition:
United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

4.02USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$4.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,301,472
52-wk High
$6.68
52-wk Low
$1.75

Chart for

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry,... (more)

Overall

Beta: 2.51
Market Cap(Mil.): $740.79
Shares Outstanding(Mil.): 173.08
Dividend: --
Yield (%): --

Financials

  GERN.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -0.17 -- --
ROI: -25.57 -5.87 13.17
ROE: -25.57 -7.71 15.15

BRIEF-Geron Entered Into Market Issuance Agreement With B. Riley FBR

* GERON - ENTERED AT THE MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR TO ISSUE AND SELL ITS COMMON STOCK WITH OFFERING PRICE OF UP TO $100 MILLION Source http://bit.ly/2Is6vuy Further company coverage:

May 18 2018

BRIEF-Geron Reports Q1 Revenue $318,000

* GERON CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

BRIEF-Geron Corporation Reports Q4 Loss Per Share $0.05

* ORATION REPORTS FOURTH QUARTER AND ANNUAL 2017 FINANCIAL RESULTS AND RECENT EVENTS

Mar 16 2018

BRIEF-Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019

* GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​ Source text (http://bit.ly/2COKF0K) Further company coverage:

Jan 08 2018

Earnings vs. Estimates